{"id":51411,"date":"2022-11-30T19:02:25","date_gmt":"2022-11-30T18:02:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/"},"modified":"2022-11-30T19:02:25","modified_gmt":"2022-11-30T18:02:25","slug":"additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/","title":{"rendered":"Additional US$ 4 Million Received for Next Development Steps of MedinCell’s 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive"},"content":{"rendered":"
\n

MONTPELLIER, France–(BUSINESS WIRE)–MedinCell<\/b> (Paris:MEDCL) h<\/b>as received an additional US$ 4 million payment from the Bill & Melinda Gates Foundation<\/b>\n<\/p>\n

<\/a><\/p>\n

\nThis amount is intended to finance the next steps of MedinCell\u2019s program mdc-WWM in readiness to initiate the first clinical trial end of 2023<\/b>\n<\/p>\n

\nIt follows US$ 11,8 million already received as part of the two successive grants for a total of up to US$ 22,5 million from the Bill & Melinda Gates Foundation to finance the development of the program up to phase 1 completion<\/b>\n<\/p>\n

\nThe Gates Foundation has a non-exclusive license on the product for the purposes of achieving Global Access in the target low-and middle-income countries, whilst MedinCell owns all marketing rights worldwide<\/b>\n<\/p>\n

\nAccess here the complete press release<\/b><\/a>\n<\/p>\n

\nAbout MedinCell<\/b>\n<\/p>\n

\nMedinCell is a pharmaceutical company at premarketing stage that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO\u00ae<\/sup> technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO\u00ae<\/sup> technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. MedinCell collaborate with tier one pharmaceuticals companies and foundations to improve Global Health through new therapeutic options. Based in Montpellier, MedinCell currently employs more than 150 people representing over 30 different nationalities.
\n
www.medincell.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedinCell
\n
David Heuz\u00e9<\/strong>
Head of Communications<\/strong>
david.heuze@medincell.com<\/a>
+33 (0)6 83 25 21 86\n<\/p>\n

\nNewCap
\n
Louis-Victor Delouvrier\/Olivier Bricaud<\/strong>
Investor Relations<\/strong>
medincell@newcap.eu<\/a>
+33 (0)1 44 71 94 94\n<\/p>\n

\nNewCap
<\/b>Nicolas Merigeau<\/strong>
Media Relations<\/strong>
medincell@newcap.eu<\/a>
+33 (0)1 44 71 94 94\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MONTPELLIER, France–(BUSINESS WIRE)–MedinCell (Paris:MEDCL) has received an additional US$ 4 million payment from the Bill & Melinda Gates Foundation This amount is intended to finance the next steps of MedinCell\u2019s program mdc-WWM in readiness to initiate the first clinical trial end of 2023 It follows US$ 11,8 million already received as part of the two … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51411","6":"format-standard","7":"category-industry"},"yoast_head":"\nAdditional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Additional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MONTPELLIER, France–(BUSINESS WIRE)–MedinCell (Paris:MEDCL) has received an additional US$ 4 million payment from the Bill & Melinda Gates Foundation This amount is intended to finance the next steps of MedinCell\u2019s program mdc-WWM in readiness to initiate the first clinical trial end of 2023 It follows US$ 11,8 million already received as part of the two ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-30T18:02:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221130005950\/en\/1651415\/21\/Logo_MedinCell_registered.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Additional US$ 4 Million Received for Next Development Steps of MedinCell’s 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive\",\"datePublished\":\"2022-11-30T18:02:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\\\/\"},\"wordCount\":326,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221130005950\\\/en\\\/1651415\\\/21\\\/Logo_MedinCell_registered.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\\\/\",\"name\":\"Additional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221130005950\\\/en\\\/1651415\\\/21\\\/Logo_MedinCell_registered.jpg\",\"datePublished\":\"2022-11-30T18:02:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221130005950\\\/en\\\/1651415\\\/21\\\/Logo_MedinCell_registered.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221130005950\\\/en\\\/1651415\\\/21\\\/Logo_MedinCell_registered.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Additional US$ 4 Million Received for Next Development Steps of MedinCell’s 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Additional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/","og_locale":"en_US","og_type":"article","og_title":"Additional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive - Pharma Trend","og_description":"MONTPELLIER, France–(BUSINESS WIRE)–MedinCell (Paris:MEDCL) has received an additional US$ 4 million payment from the Bill & Melinda Gates Foundation This amount is intended to finance the next steps of MedinCell\u2019s program mdc-WWM in readiness to initiate the first clinical trial end of 2023 It follows US$ 11,8 million already received as part of the two ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-30T18:02:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221130005950\/en\/1651415\/21\/Logo_MedinCell_registered.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Additional US$ 4 Million Received for Next Development Steps of MedinCell’s 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive","datePublished":"2022-11-30T18:02:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/"},"wordCount":326,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221130005950\/en\/1651415\/21\/Logo_MedinCell_registered.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/","url":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/","name":"Additional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221130005950\/en\/1651415\/21\/Logo_MedinCell_registered.jpg","datePublished":"2022-11-30T18:02:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221130005950\/en\/1651415\/21\/Logo_MedinCell_registered.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221130005950\/en\/1651415\/21\/Logo_MedinCell_registered.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/additional-us-4-million-received-for-next-development-steps-of-medincells-6-month-active-injectable-bioresorbable-subcutaneous-contraceptive\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Additional US$ 4 Million Received for Next Development Steps of MedinCell’s 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51411"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51411\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51411"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51411"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}